Cadrenal Therapeutics, Inc. Common Stock

CVKD

$1.28

-3.76%

N/A-$0.05

Healthcare

Biotechnology

NASDAQ

Active Trading

Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, ...

Supply Chain of CVKD

Upstream

Foundry, packaging, memory, wafers, components, and input vendors.

Upstream

Undisclosed CDMO / API Manufacturer

Undisclosed Clinical CRO

Specialty Chemical Suppliers (Unidentified)

Undisclosed CDMO / API Manufacturer

Contract Development & Manufacturing Organization for tecarfarin active pharmaceutical ingredient and drug product supply for clinical trials

Undisclosed Clinical CRO

Contract Research Organization managing clinical trial operations, site management, data management, and regulatory submissions for tecarfarin clinical studies

Specialty Chemical Suppliers (Unidentified)

Tier 2 raw chemical and reagent suppliers to the CDMO manufacturing tecarfarin API

Downstream

Customers, distributors, OEMs, and channels that absorb output.

Downstream

No Commercial Customers (Pre-Revenue Stage)

Potential Future Commercialization Partner(s)

No Commercial Customers (Pre-Revenue Stage)

Cadrenal Therapeutics has no approved products and therefore no commercial downstream customers. Target end-users would be ESRD patients with AFib treated at dialysis centers and nephrology/cardiology clinics.

Potential Future Commercialization Partner(s)

As a small cap biotech, Cadrenal may seek a licensing/commercialization partner for tecarfarin if approved. No public partnership has been announced as of the latest filings.

Proxies

Public comparables and monitoring names used as representatives for the analysis.

Proxies

Esperion Therapeutics

Annexon Biosciences

Acumen Pharmaceuticals

Esperion Therapeutics

NASDAQ:ESPR

Comparable small/mid-cap clinical-stage cardiovascular biotech that uses external CDMO/CRO partners and progressed from Phase 3 to commercialization; useful proxy for supply chain structure of a CV-focused development-stage company.

Annexon Biosciences

NASDAQ:ANNX

Clinical-stage biotech with single-asset risk profile and similar reliance on contract manufacturing and research organizations for clinical supply.

Acumen Pharmaceuticals

NASDAQ:ABOS

Small-cap clinical-stage biotech with virtual operational model and external manufacturing partners, providing a structural supply chain proxy.

Geographic

Region-level exposures that can distort the supply network.

Geographic

United States

Global (Unspecified CDMO Locations)

Cadrenal Therapeutics (Ponte Vedra Beach, FL)

Undisclosed CDMO / API and Drug Product Manufacturer

United States

Operational & Regulatory Headquarters

Cadrenal Therapeutics (Ponte Vedra Beach, FL)NASDAQ:CVKDCorporate headquarters and principal executive offices

Global (Unspecified CDMO Locations)

Manufacturing Supply Chain

Undisclosed CDMO / API and Drug Product ManufacturerProduct manufacturing for clinical trial supply; location(s) not publicly confirmed

Concentration

Customer, supplier, or partner concentration exposures that can distort the supply network.

Other

Critical

Single-asset risk — tecarfarin is Cadrenal's only drug candidate. Any supply chain disruption impacting tecarfarin clinical material halts all pipeline progress.

Other

High

CDMO/CRO dependency — as a virtual clinical-stage company, Cadrenal relies entirely on external contract partners for drug manufacturing and clinical trial execution. Loss of key contract partner would cause significant delays.

Revenue mix

How the target's revenue mix translates into supply-chain leverage and dependency.

Product Revenue

0.0%

$0.0B

No commercial revenue — all spend is R&D/clinical-stage. Supply chain is limited to CRO/CDMO service procurement, clinical materials, and API manufacturing.

Grant / Other Income

0.0%

Any small amounts from grants or interest income have no material supply chain implication.

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer